Global biosimilar regulatory harmonization will be needed to reduce development costs and improve patient access, despite ...

Regeneron Pharmaceuticals, Inc. faces Eylea revenue decline but shows growth potential with Dupixent & Libtayo. Click for ...

Regenerative medicine is the branch of medicine that develops methods to regrow, repair or replace damaged or diseased cells, organs or tissues. Regenerative medicine includes the generation and ...

A college student from Anthony is speaking out after Blue Cross and Blue Shield of Kansas denied a medicine she has been ...

India has a strong pharma network, with more than 10,000 manufacturing facilities, over 3,000 pharma companies.

Celltrion today announced the U.S. launch of STEQEYMA��(ustekinumab-stba), a biosimilar to STELARA� (ustekinumab), following approval by the U.S. Food and Drug Administration (FDA) in December 2024.

Omlyclo is used for the treatment of moderate to severe persistent asthma, chronic rhinosinusitis with nasal polyps, ...

Biosimilars — nearly identical and more affordable alternatives to biologics — can significantly lower treatment costs by 50–75%.

Achieving cost sustainability in inflammatory bowel disease (IBD) care requires expanding access to cost-effective treatments ...

The FDA has approved Celltrion’s OMLYCLO (omalizumab-igec) as the first and only biosimilar designated as interchangeable ...

Celltrion Inc., a major South Korean biopharmaceutical firm, said Monday its biosimilar for asthma and other chronic allergic diseases has obtained approval for U.S. sales. The U.S. Food and Drug ...